Hsbc Holdings PLC Grows Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hsbc Holdings PLC grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 195.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,519 shares of the company's stock after purchasing an additional 2,988 shares during the period. Hsbc Holdings PLC's holdings in Krystal Biotech were worth $718,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. US Bancorp DE boosted its holdings in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after buying an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after buying an additional 121 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after buying an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its holdings in shares of Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after buying an additional 123 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of several research reports. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Citigroup raised their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 6th. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $218.63.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $4.94 during midday trading on Friday, reaching $132.23. The company had a trading volume of 329,798 shares, compared to its average volume of 300,407. The stock has a fifty day moving average price of $171.56 and a 200 day moving average price of $170.01. The firm has a market cap of $3.82 billion, a PE ratio of 44.22 and a beta of 0.79. Krystal Biotech, Inc. has a fifty-two week low of $131.71 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).